Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin
暂无分享,去创建一个
[1] B. Teicher. Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.
[2] R. Audisio,et al. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion , 2004, Clinical & Experimental Metastasis.
[3] R. Wagner,et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. , 2002, Cancer research.
[4] Y. Gho,et al. Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.
[5] E. Chavakis,et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti‐angiogenic effects of endostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] R. Timpl,et al. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. , 2002, Cancer research.
[7] B. Bochner,et al. Development of lentiviral vectors for antiangiogenic gene delivery , 2001, Cancer Gene Therapy.
[8] G. Adessi,et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. , 2001, The Journal of urology.
[9] A. Nienhuis,et al. Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model , 2001, Cancer Gene Therapy.
[10] D. Mukhopadhyay,et al. Cell surface glypicans are low-affinity endostatin receptors. , 2001, Molecular cell.
[11] T. Veikkola,et al. Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Ahn,et al. Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] I. Verma,et al. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[14] K. W. Kim,et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.
[15] R. Vile,et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy , 2000, Gene Therapy.
[16] D. Kohn,et al. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. , 1999, Blood.
[17] R. Bicknell,et al. Antiangiogenic gene therapy , 1999, Gene Therapy.
[18] D. Kohn,et al. Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.
[19] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[20] V. Sukhatme,et al. Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.
[21] A. Harris,et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. , 1999, The Journal of urology.
[22] A. Sagalowsky,et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.
[23] V. Sukhatme,et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. , 1999, Cancer research.
[24] D. Trono,et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.
[25] H. Grossman,et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. , 1998, The Journal of urology.
[26] U. Stenram. Re: Gene therapy strategies for tumor antiangiogenesis. , 1998, Journal of the National Cancer Institute.
[27] S. Campbell,et al. Molecular mediators of angiogenesis in bladder cancer. , 1998, Cancer research.
[28] R. Kumar,et al. Angiogenic molecules and cancer metastasis. , 1998, In vivo.
[29] R. Crystal,et al. Gene therapy strategies for tumor antiangiogenesis. , 1998, Journal of the National Cancer Institute.
[30] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[31] Luigi Naldini,et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.
[32] S. Groshen,et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.
[33] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[34] A. Harris,et al. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. , 1997, Cancer research.
[35] J. Folkman,et al. Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.
[36] D. Hanahan,et al. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.
[37] F. Gage,et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Folkman,et al. Fighting cancer by attacking its blood supply. , 1996, Scientific American.
[39] S. Groshen,et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.
[40] P. Carroll,et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. , 1995, The Journal of urology.
[41] H. Shimada,et al. Host organ specifically determines cancer progression. , 1995, Cancer research.
[42] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[43] P Vaupel,et al. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.
[44] I. Pastan,et al. Inhibition of VSV binding and infectivity by phosphatidylserine: Is phosphatidylserine a VSV-binding site? , 1983, Cell.